Key figures

• 1^st independent French pharmaceutical company

• Over 20 000 employees, including nearly 3000 researchers preparing the drugs of the future

  

• 25% of turnover invested in Research and Development

• 44 new chemical entities currently under development in the following therapeutic fields: cardiovascular diseases, central nervous system and psychiatry, cancer research, diabetes and metabolism, and rheumatology

• Present in 140 countries over 5 continents

• 92% of Servier's medicines are prescribed internationally